Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGR005: Pilot study of NGR-hTNF with oxaliplatin-based chemotherapy in metastatic colorectal cancer
2007-003668-24Phase 2Active
- Sponsor
- MolMed
- Start
- Dec 2007
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of NGR-TNF in colorectal cancer (CRC) (2 cohorts), sponsored by MolMed. Primary endpoint: Feasibility and safety of NGR-hTNF at low and high doses in combination with oxaliplatin-based chemotherapy. Started Dec 2007; status: active.
02
Drugs
NGR-TNF
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2007-003668-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003668-24.